BASE-LINE SERUM-CHOLESTEROL AND TREATMENT EFFECT IN THE SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY (4S)

We examined the relation between the risk of major coronary events (co ronary death and non-fatal myocardial infarction) and baseline cholest erol revels in patients with coronary heart disease, randomised to pla cebo or simvastatin therapy in the Scandinavian Simvastatin Survival S tudy (4S). The relative risk reduction in the simvastatin group was 35 % (95% CI 15-50) in the lowest quartile of baseline low-density-lipopr otein cholesterol and 36% (19-49) in the highest. Simvastatin signific antly reduced the risk of major coronary events in all quartiles of ba seline total, high-density-lipoprotein, and low-density-lipoprotein ch olesterol, by a similar amount in each quartile.